Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2021-04-14 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2021. It is addressed to stock exchanges and confirms dematerialization/rematerialization of securities and related compliance. The document is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or management discussion but is a formal attestation related to securities regulations. The document length is 3586 characters, which is relatively short and consistent with a certificate or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance certificate and not a financial report or announcement.
2021-04-14 English
ESOP/ESOS/ESPS
Capital/Financing Update Classification · 95% confidence The document is a formal communication dated April 6, 2021, from Bliss GVS Pharma Ltd. It informs about the grant of employee stock options under the company's ESOP 2019 plan. The content references regulatory compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and details the approval of stock options by the Nomination and Remuneration Committee. The document includes an annexure listing details of the options granted. This is a regulatory announcement about a capital-related event (grant of stock options) rather than a full financial report or management discussion. It does not contain financial statements or earnings data, nor is it a report publication announcement or certification. The nature of the document fits best under Capital/Financing Update (CAP) as it relates to the company's capital structure changes via stock options granted to employees.
2021-04-06 English
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'') read with Para B of Part A of Schedule III of Listing Regulations ....
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Bliss GVS Pharma Limited regarding the grant of employee stock options under their Employee Stock Options Plan 2019. It references regulatory compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and details the approval of stock options granted to employees by the Nomination and Remuneration Committee of the Board. The content is focused on the grant of options, which is a capital-related update rather than a full financial report or earnings release. The document is not a full annual or quarterly report, nor is it a transcript, audit report, or legal proceeding. It is an update on a financing-related activity (employee stock options grant). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a mere announcement of a report but a substantive update.
2021-04-06 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Chief Manager - Surveillance at the National Stock Exchange of India, responding to a query about unusual price movement in the company's shares. It clarifies that there is no new relevant information or announcement affecting the share price and confirms compliance with disclosure regulations. The letter is a regulatory communication clarifying price movement and compliance, not a financial report, earnings release, or any other detailed filing. It does not contain financial data or detailed report content but serves as a regulatory filing to address surveillance concerns. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and the content is a formal regulatory response, not a report or announcement of a report publication.
2021-04-01 English
Kindly refer the attachment.
Regulatory Filings Classification · 95% confidence The document is a letter from Bliss GVS Pharma Ltd. addressed to BSE Limited, providing a clarification on the price movement of the company's shares. It references a regulatory inquiry under SEBI Listing Regulations and states that there is no new information affecting share price that requires disclosure. The document is short (1868 characters) and serves as a regulatory communication rather than a financial report or announcement of results. It does not contain financial data, management discussion, or report content. It is a regulatory compliance communication responding to a stock exchange query, fitting the category of Regulatory Filings (RNS).
2021-04-01 English
Trading Window
Regulatory Filings Classification · 90% confidence The document is extremely short (291 characters) and contains only address and listing department information for stock exchanges without any substantive content, financial data, or report details. It does not contain any report, announcement of voting results, management changes, or financial results. Given the lack of content and the nature of the text, it fits best as a Regulatory Filing (RNS) which is a fallback category for miscellaneous filings that do not fit other categories.
2021-03-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.